AKT1 and endometrial serous adenocarcinoma: [61] demonstrated that Ipatasertib, our reference compound, effectively inhibited cell proliferation in uterine serous carcinoma cell lines with IC50 values of 6.62 μM for PTEN wild‐type ARK1 cells and 2.05 μM for PTEN null SPEC‐2 cells, confirming its biological activity against the Akt target.